89SrCl2 治疗11 例肿瘤骨转移的临床观察

 目的　探讨⁸⁹SrCl₂ 治疗转移性骨肿瘤的临床应用价值。方法　 1 1例经证实为肿瘤骨转移患者接受 ⁸⁹SrCl₂ 4 mci静脉注射治疗 ,治疗后至随访时间为 3个月～ 1年。结果　止痛总有效率72 .8% ;显效 45.5% ( 5/1 1 ) ;有效 2 7.3% ( 3/1 1 ) ;止痛起效时间较快 ,缓解骨痛持续时间较长 ,骨髓抑制不明显。结论　⁸⁹SrCl₂治疗肿瘤骨转移患者有缓解疼痛、提高生存质量的作用.     

The hederagenin saponin SMG-1 is a natural FMLP receptor inhibitor that suppresses human neutrophil activation

The pericarp of Sapindus mukorossi Gaertn is traditionally used as an expectorant in Japan, China, and Taiwan. Activated neutrophils produce high concentrations of the superoxide anion (O₂⁻) and elastase known to be involved in airway mucus hypersecretion. In the present study, the anti-inflammatory functions of hederagenin 3-O-(3,4-O-di-acetyl-α-l-arabinopyranoside)-(1→3)-α-l-rhamnopyranosyl-(1→2)-α-l-arabinopyranoside (SMG-1), a saponin isolated from S. mukorossi, and its underlying mechanisms were investigated in human neutrophils. SMG-1 potently and concentration-dependently inhibited O₂⁻ generation and elastase release in N-Formyl-Met-Leu-Phe (FMLP)-activated human neutrophils. Furthermore, SMG-1 reduced membrane-associated p47^phox expression in FMLP-induced intact neutrophils, but did not alter subcellular NADPH oxidase activity in reconstituted systems. SMG-1 attenuated FMLP-induced increase of cytosolic calcium concentration and phosphorylation of p38 MAPK, ERK, JNK, and AKT. However, SMG-1 displayed no effect on cellular cAMP levels and activity of adenylate cyclase and phosphodiesterase. Significantly, receptor-binding analysis showed that SMG-1 inhibited FMLP binding to its receptor in a concentration-dependent manner. In contrast, neither phorbol myristate acetate-induced O₂⁻ generation and MAPKs activation nor thapsigargin-caused calcium mobilization was altered by SMG-1. Taken together, our results demonstrate that SMG-1 is a natural inhibitor of the FMLP receptor, which may have the potential to be developed into a useful new therapeutic agent for treating neutrophilic inflammatory diseases.     

唑来膦酸联合89 S r治疗恶性肿瘤晚期多发骨转移的疗效观察

目的 探讨恶性肿瘤晚期多发骨转移患者采用唑来膦酸联合89 Sr治疗的临床疗效.方法 将90例恶性肿瘤晚期多发骨转移患者,按照随机抛硬币法将其分组为对照组(唑来膦酸静脉滴注)与观察组(唑来膦酸静脉滴注联合89 Sr静脉注射),各45例.采用疼痛视觉模拟法(VAS)评价两组患者治疗前、后疼痛情况,通过问卷调查表调查两组患者治疗前、后生活质量改善情况,统计两组临床疗效及不良反应.结果 治疗后,两组患者VAS评分及生活质量各项指标均较治疗前明显改善,而观察组各项指标改善程度优于对照组,P<0.05.观察组治疗临床有效率为84.4%,明显高于对照组(66.7%),P<0.05;两组患者不良反应率比较,P>0.05.结论 唑来膦酸联合89 Sr治疗恶性肿瘤晚期多发骨转移可缓解患者疼痛,提高临床治疗效果,改善其生活质量,同时不会增加治疗期间所产生的不良反应,因此值得深入研究以利于其推广应用.     

89SrCl2联合125I粒子植入术治疗恶性肿瘤骨转移的疗效及安全性

目的 探讨89SrCl2联合125I粒子植入术治疗恶性肿瘤骨转移的疗效及安全性.方法 选择恶性肿瘤骨转移患者600例作为研究对象,根据随机信封抽签原则分为观察组与对照组,各300例患者.对照组给予125I粒子植入术治疗,观察组在对照组治疗的基础上给予89SrCl2治疗,都治疗观察3个月.结果 所有患者都完成治疗.治疗后所有患者肝肾功能未见明显异常.观察组的疼痛缓解总有效率(97.0％)明显好于对照组(86.3％)(P＜0.05).观察组的治疗总有效率(93.3％)明显高于对照组(76.7％)(P＜0.05).观察组与对照组治疗后的生存质量评分分别为(89.43±5.39)分和(78.20±8.22)分,都明显高于治疗前的(56.30±5.94)分和(57.10±6.89)分(JP＜0.05),且治疗后观察组的生存质量评分明显高于对照组(P＜0.05).结论 89SrCl2联合125I粒子植入术治疗恶性肿瘤骨转移的安全性比较好,能够缓解骨痛,提高治疗疗效,有利于生存质量的改善,具有很好的应用价值.     

多西他赛联合PD-1/PD-L1抑制剂二线治疗晚期非小细胞肺癌的临床分析

背景与目的程序性死亡受体1（programmed cell death 1, PD-1）/程序性死亡配体1（programmed cell death ligand 1, PD-L1）抑制剂和多西他赛作为晚期非小细胞肺癌（non-small cell lung cancer, NSCLC）患者的标准二线治疗方案，治疗效果有限。多西他赛联合PD-1/PD-L1抑制剂是否能增加疗效并使患者更好地获益少有报道。本研究旨在探索多西他赛联合PD-1/PD-L1抑制剂二线治疗驱动基因阴性的Ⅳ期NSCLC的临床疗效和安全性。方法选取2018年10月1日-2020年12月31日在山东省肿瘤医院就诊的Ⅳ期NSCLC患者118例，依据治疗方法不同分为观察组（n=69）和对照组（n=49），观察组患者接受多西他赛联合PD-1/PD-L1抑制剂治疗，对照组患者接受PD-1/PD-L1抑制剂治疗，比较两组患者的临床疗效及3级以上不良反应发生情况。结果观察组疾病控制率（disease control rate, DCR）（89.9%）高于对照组（73.5%）（P=0.019），客观缓解率（objective response rate, ORR）（24.6%）与对照组（16.3%）比较差异无统计学意义（P=0.276）。随访至2021年6月22日，观察组中位无进展生存时间（progression-free survival, PFS）（7.17个月）长于对照组（4.43个月)（P=0.027）。观察组1年无进展生存率为15.6%，对照组为7.7%，差异无统计学差异（P=0.205）。治疗期间两组不良反应多为1级-2级，均可耐受，观察组患者骨髓抑制发生率高于对照组（P < 0.05），余不良反应与对照组无统计学差异。Cox回归分析结果显示体能状态（performance status, PS）（P=0.020）及年龄（P=0.049）是多西他赛联合PD-1/PD-L1抑制剂治疗效果的独立预后因素。结论驱动基因阴性Ⅳ期NSCLC患者应用多西他赛联合PD-1/PD-L1抑制剂二线治疗可提高疾病控制率，延长无进展生存时间，不良反应可耐受。     

153Sm-EDTMP与89Srcl放射治疗肿瘤骨转移疼痛的评估

目的:对比研究放射性核素制剂153钐-乙二铵四甲基磷酸(153sm-EDTMP)与89氯化锶(89Srcl)治疗肿瘤骨转移疼痛的疗效.方法:对123例肿瘤骨转移患者按个人意愿结合家庭经济情况分组,Ⅰ组:153Sm-EDTMP治疗组;Ⅱ组:89Srcl治疗组.对治疗前后行SPECT全身骨扫描及骨痛评估.结果:153Sm-EDTMP及89Srcl治疗肿瘤骨转移疼痛的有效率分别为77.78%、81.82%;153Sm-EDTMP及89Srcl治疗肺癌、乳腺癌、前列腺癌及其他肿瘤骨转移有效率分别为64.71%、89.47%、90.00%、62.50%;72.73、86.67%、100%、75.00%,存在明显差异(P<0.05);153Sm-EDTMP及89Srcl治疗肿瘤骨转移疼痛起效时间分别为(10.1±3.2)天、(7.3±1.8)天,止痛持续时间分别为(25.5±8.3)周、(30.1±10.4)周,治疗花费分别为(4.1±0.5)千元、(8.3±0.8)千元,存在明显差异(P<0.01);153Sm-EDTMP及89Srcl治疗肿瘤骨转移疼痛的不良反应率分别为4.4%、3.0%,存在明显差异(P<0.05).结论:153Sm-EDTMP及89Srcl治疗肿瘤骨转移疼痛均可取得较高有效率,三种常见肿瘤有效率从高到低分别前列腺癌、乳腺癌、肺癌,起效时间、持续时间及治疗花费均有明显差异,应结合患者具体情况选用.     

The efficacy of 89Sr combined with 99Tc-MDP in the treatment of the advanced breast cancers with bone metastases

Objective： The aim of our study was to evaluate the efficacy of 89Sr combined with Technetium [^99Tc] Methylene- diphosphonate Injection （^99Tc-MDP） in the treatment of cancer pain in the advanced breast cancers with bone metastases. Methods： A total of 80 patients with various degrees of bone pain due to multiple metastases of breast cancer were treated with ^89Sr combined with ^99Tc-MDP. ^89Sr was given intravenously at 4mCi on day 1 during the 3-month schedule. After 7 days, ^99Tc-MDP was given at 22 rag/day on days 1-10 during the 1-month schedule, for 3 to 6 months. Results： The effective rate of relieving pain was 83.75%. The effective rate of curing bone metastases was 81.25%. So there was a significant improvement in the quality of life of the patients. Conclusion： ^89Sr combined with ^99Tc-MDP are effective in the treatment of cancer pain in the breast cancers with bone metastasis, and can obviously repair the bone destruction caused by metastases, thereby improving the quality of life in advanced breast cancer patients with bone metastases.     

^89SrCl2和^153Sm—EDTMP治疗转移性骨肿瘤骨痛的疗效比较

目的：对比评价^89SrCl2和^153Sm—EDTMP治疗转移性骨肿瘤的临床疗效和不良反应。方法：对124例有不同程度骨痛,伴或不伴有活动受限的广泛转移性骨肿瘤患者分成二组,40例应用^89SrCl2（^89Sr组）治疗,84例用^153Sm—EDTMP（^153Sm组）治疗。结果：^89SrCl2和^153Sm—EDTMP对骨痛止痛总有效率分别为80％和78．6％,差异无显著性,但前者的病灶变化例数明显高于后者。结论：对经济条件好,存活时间较长,不便到医院治疗的多发转移性骨肿瘤骨痛患者可首选^89SrCl2治疗     

Antibiofilm phenylethanoid glycosides from Penstemon centranthifolius

Bioassay‐guided fractionation of the antibacterial ethyl acetate‐ethanol (50 : 50) extract obtained from the aerial parts of Penstemon centranthifolius led to the isolation of six phenylethanoid glycosides (1–6) and eleven iridoid glycosides (7–17). Their structures were determined on the basis of spectroscopic analysis and comparison with the literature. Among them, two phenylethanoid glycosides, 4″′‐O–acetylverbascoside (1) and verbascoside (2), were found to show significant inhibition of the formation of bacterial biofilms by Escherichia coli UTI89. Compound 1 showed 77% biofilm inhibition at 2.5 µg/mL, and compound 2 showed 60% inhibition at 5 µg/mL. Copyright © 2009 John Wiley & Sons, Ltd.